Since its Food and Drug Administration (FDA) approval in 2019 and subsequent EMA approval in 2020, Vertex Pharmaceuticals’ Trikafta (ETI and ivacaftor) has revolutionised CF care, with global ...

“I hear almost every day from people who were really in trouble, with cystic fibrosis severely beginning to affect their chance of survival,” says Collins. “Now, after going on ...

Vertex is in the early stages of its all-important Trikafta launch, but, at least so far, things are going according to plan. The first patients have been prescribed the triple-combo cystic ...

Trikafta, made by Vertex Pharmaceuticals, is, as its name suggests, a combination of three drugs. It works for 90 percent of patients with cystic fibrosis, and will be priced at $311,000 per year.

Eligible 6-11 year-olds with cystic fibrosis will be able to receive Trikafta through the Pharmaceutical Benefits Scheme from May 1, 2023. The drug has been credited with improving the life ...

Ontario is one of three provinces that announced last month it would provide eligible patients with Trikafta, which costs roughly $300,000 a year at its list price, under the Ontario Health ...